We analyzed the signaling pathways initiated by endothelin receptors ETA and ETB in intestinal circular and longitudinal smooth muscle cells. The response to endothelin-1 (ET-1) consisted of two phases in both cell types. The initial, transient phase of contraction and phosphorylation of 20-kDa myosin light chain (MLC20) was mediated additively by ETA and ETB receptors and initiated by G␣q-, Ca 2ϩ /calmodulin-dependent activation of MLC kinase. In contrast, the sustained phase was mediated selectively by ETA receptors via a pathway involving sequential activation of G␣13, RhoA, and Rho kinase, resulting in phosphorylation of MYPT1 at Thr 696 and phosphorylation of MLC20. Although PKC was activated, CPI-17 was not phosphorylated and hence did not contribute to inhibition of MLC phosphatase. The absence of CPI-17 phosphorylation by PKC reflected active dephosphorylation of CPI-17 by protein phosphatase 2A (PP2A). PP2A was activated via a pathway involving ETB-dependent stimulation of p38 MAPK activity. CPI-17 phosphorylation was unmasked in the presence of the ETB antagonist BQ-788, but not the ETA antagonist BQ-123, and in the presence of a low concentration of okadaic acid, which selectively inactivates PP2A. The resultant phosphorylation of CPI-17 was blocked by bisindolylmaleimide, providing direct confirmation that it was PKC dependent. We conclude that the two phases of the intestinal smooth muscle response to ET-1 involve distinct receptors, G proteins, and signaling pathways. The sustained response is mediated via selective ET A-dependent phosphorylation of MYPT1. In contrast, ETB initiates an inhibitory pathway involving p38 MAPK-dependent activation of PP2A that causes dephosphorylation of CPI-17. endothelin receptor type A; endothelin receptor type B; myosin phosphatase targeting subunit THE DISCOVERY OF A POTENT, endothelium-derived vasoconstrictor led soon after to the cloning and characterization of three 21-amino acid isopeptides: endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3) (46). The peptides are variously expressed in different tissues and occur in different proportions (6, 7, 37) . Only ET-1 is expressed and released from endothelial cells. Two endothelin receptors, ET A and ET B , have been cloned and are characterized by a distinctive order of affinity (ET A : ET-1 ϭ ET-2 Ͼ ET-3; ET B : ET-1 ϭ ET-2 ϭ ET-3) (2, 38, 39). The mammalian counterpart of a third receptor type, ET C , has not been cloned (26). Knockout of the genes encoding ET-1 or ET A results in severe craniofacial and vascular malformations, suggesting a role for ET A in the development of the heart and great vessels (5). Knockout of the genes encoding ET-3 or ET B results in aganglionic megacolon akin to Hirschprung's disease in humans, suggesting a role for ET B receptors in the normal development of neural crest cells (3). A functional role for endothelin in the regulation of gastrointestinal smooth muscle activity is suggested by the presence of endothelin-like immunoreactivity in enteric neurons innervating smooth muscle (8, 9, 16) .
THE DISCOVERY OF A POTENT, endothelium-derived vasoconstrictor led soon after to the cloning and characterization of three 21-amino acid isopeptides: endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3) (46) . The peptides are variously expressed in different tissues and occur in different proportions (6, 7, 37) . Only ET-1 is expressed and released from endothelial cells. Two endothelin receptors, ET A and ET B , have been cloned and are characterized by a distinctive order of affinity (ET A : ET-1 ϭ ET-2 Ͼ ET-3; ET B : ET-1 ϭ ET-2 ϭ ET-3) (2, 38, 39) . The mammalian counterpart of a third receptor type, ET C , has not been cloned (26) . Knockout of the genes encoding ET-1 or ET A results in severe craniofacial and vascular malformations, suggesting a role for ET A in the development of the heart and great vessels (5) . Knockout of the genes encoding ET-3 or ET B results in aganglionic megacolon akin to Hirschprung's disease in humans, suggesting a role for ET B receptors in the normal development of neural crest cells (3) . A functional role for endothelin in the regulation of gastrointestinal smooth muscle activity is suggested by the presence of endothelin-like immunoreactivity in enteric neurons innervating smooth muscle (8, 9, 16) .
A subtype of ET B receptor (ET B1 ) mediates the ability of ET-1 and ET-3 to stimulate nitric oxide (NO) formation in endothelial cells via Ca 2ϩ /calmodulin-dependent activation of endothelial NO synthase (eNOS) and/or via G␤␥ i -dependent activation of Akt and phosphorylation of eNOS (14, 24) . ET-1 released from endothelial cells or via the circulation interacts with ET A and/or ET B2 receptors to cause contraction of vascular smooth muscle cells. The signaling pathway in vascular or visceral smooth muscle involves stimulation of phosphoinositide (PI) hydrolysis and Ca 2ϩ release, presumed to occur via coupling of ET A or ET B to G q and, less often, to G i (7, 11, 36, 37) . A more complex pathway is present in iris sphincter and ciliary smooth muscle, where ET-1 activates cytoplasmic phospholipase 2 (cPLA 2 ) and induces prostaglandin E 2 (PGE 2 )-dependent Ca 2ϩ mobilization and cAMP formation (1, 15) . In other regions, for example, intestinal muscle and internal anal sphincter, ET-1 induces a transient nerve-mediated relaxation followed by a sustained contraction (4, 10, 12, 25) . Gohla et al. (11) provided the first evidence of specific G proteins activated by ET-1, using cultured aortic smooth muscle cells. ET-1 was shown to activate mainly G q and G 13 and to stimulate 20-kDa myosin light chain (MLC 20 ) phosphorylation and contraction; the latter were blocked by inhibitors of PI hydrolysis, MLC kinase (MLCK), RhoA, and Rho kinase, suggesting the involvement of MLCK and Rho kinase pathways. The specificity of endothelin receptors mediating these pathways and the downstream components of RhoA-dependent pathway involved in inactivation of MLC phosphatase and stimulation of MLC 20 phosphorylation were not further analyzed.
Recent studies with other agonists in vascular and visceral smooth muscle suggest that the MLCK-and RhoA-dependent pathways are temporally distinct and mediated by specific receptors and G proteins (18, 19, 31, 40, 41) . In the present study, we have examined the role of ET A and ET B receptors in the regulation of each pathway and have shown that both ET A and ET B mediate G q -dependent activation of MLCK and transient stimulation of MLC 20 phosphorylation and contraction, whereas only ET A mediates G 13 
MATERIALS AND METHODS
Preparation of dispersed smooth muscle cells. Muscle cells were isolated separately from the circular and longitudinal muscle layers of rabbit intestine by 30-min incubation at 31°C in HEPES medium with type II collagenase (0.1%) and soybean trypsin inhibitor (0.1%) as described previously (27) (28) (29) (30) (31) (32) . The partly digested strips were washed, and muscle cells were allowed to disperse spontaneously for 30 min. The cells were harvested by filtration through 500-m Nitex and were centrifuged twice at 350 g for 10 min.
Expression of ET receptors. Specific primers were designed based on homologous sequences in human, rat, and mouse cDNAs for ET A and ETB. ETA primers were 5Ј-CCGGAGAGATACAGCGCTA-ATC-3Ј (forward) and 5Ј-CAGCTTGCAGAGAAACACTCC-3Ј (reverse); the expected size of the PCR product was 414 bp. ET B primers were 5Ј-GACATCGCCCGCAAGCCGGTGCGG-3Ј (forward) and 5Ј-GTAGGTGTTAATGGGTATGTC-3Ј (reverse); the expected size of the PCR product was 478 bp. Total RNA (5 g) isolated from cultured circular and longitudinal smooth muscle cells was reversibly transcribed and amplified by PCR under standard conditions as described previously (43, 47) . The PCR products were separated by electrophoresis in 1.2% agarose gel in the presence of ethidium bromide, visualized by ultraviolet fluorescence, and recorded using a ChemiImager 4400 fluorescence system. The PCR products were purified and sequenced.
Selective protection of ET A and ETB receptors. A technique for selective receptor protection previously used to determine the coexistence and function of various G protein-coupled receptors was used to characterize the signaling pathways mediated by ET A and ETB receptors (29, 30) . The technique involves protection of one receptor subtype with selective ET-1 agonists or antagonists, followed by inactivation of all unprotected receptors with a low concentration of N-ethylmaleimide (NEM; 5 M). Freshly dispersed muscle cells were incubated with an ET A or ETB antagonist at 31°C for 2 min, followed by addition of NEM for 20 min. The cells were centrifuged twice at 150 g for 10 min and resuspended in control HEPES medium for 60 min. The contractile response to ET-1 of cells treated in this fashion was compared with the response of untreated cells. As previously shown (29, 30) , muscle cells incubated with NEM without protective agent did not contract in response to receptor-linked agonists, but they responded fully to ionomycin and KCl.
Identification of endothelin-activated G proteins. Activation of specific G proteins was determined from agonist-induced increase in G␣ binding to guanosine 5Ј-O-(3-thiotriphosphate) (GTP␥S) as described previously (29, 30, 32, 35, 47) . Cells were homogenized in 20 mM HEPES (pH 7.4), the homogenates were centrifuged at 4°C for 30 min at 30,000 g, and the membranes were solubilized in 20 mM HEPES buffer containing 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). Solubilized membranes were incubated for 20 min at 37°C with 100 nM [ 35 S]GTP␥S in 10 mM HEPES with ET-1 in the presence or absence of ETB or ETA antagonist. The reaction was stopped with 10 volumes of 100 mM Tris ⅐ HCl medium (pH 8.0) containing 20 M GTP, and the membranes were incubated for 2 h on ice in wells precoated with a specific G␣ antibody. After membranes were washed with phosphate buffer, the radioactivity from each well was counted by liquid scintillation.
Assay of phospholipase C-␤ activity. Total inositol phosphates were measured using anion exchange chromatography as described previously (31, 47 45 Ca 2ϩ release was measured in permeabilized muscle cells as described previously (47) . The cells were permeabilized by treatment with saponin (35 g/ml) for 5 min and, after being washed, were resuspended in a medium containing 100 nM Ca 2ϩ , 10 M antimycin, 10 Ci/ml 45 Ca 2ϩ , 1.5 mM ATP, and ATP-regenerating system (5 mM creatine phosphate and 10 U/ml creatine kinase). Steady-state Ca 2ϩ uptake was measured after incubation for 60 min (2.38 Ϯ 0.26 nmol Ca 2ϩ /10 6 cell), and Ca 2ϩ release was determined from the decrease in steady-state 45 Ca 2ϩ cell content during the first 30 s after addition of ET-1.
Assay for RhoA activity. Activated RhoA was measured in freshly dispersed muscle cells with the use of a technique using Rhotekin as described previously (32) . Muscle cells lysates (100 g of protein) were incubated with glutathione-agarose slurry of Rhotekin at 4°C for 45 min. The beads were washed three times with the washing buffer containing 50 mM Tris ⅐ HCl (pH 7.2), 1% Triton X-100, 150 mM NaCl, 10 mM MgCl 2, 0.1 mM PMSF, 10 g/ml aprotinin, and 10 g/ml leupeptin. GTP-bound RhoA was solubilized in Laemmli sample buffer and analyzed by 15% SDS-PAGE followed by Western blot and chemiluminescence.
Assay for phospholipase D activity. Phospholipase D (PLD) activity was determined by formation of the PLD-specific product phosphatidylethanol (PEt) as described previously (28) . Smooth muscle cells (2 ϫ 10 6 cells/ml) were incubated for at 31°C for 3 h in HEPES medium with [ 3 H]myristic acid (2 Ci/ml) and then with 150 mM ethanol. The cells were centrifuged, resuspended in fresh medium, and stimulated with ET-1 for 5 min. The reaction was terminated with chloroform-methanol-HCl (100:200:2, vol/vol/vol), and the organic phase was extracted and analyzed for [ Assay for Rho kinase activity. Rho kinase activity was determined by immunokinase assay in cell extracts as described previously (31) . The immunoprecipitates were washed with phosphorylation buffer and incubated for 5 min on ice with 5 g of myelin basic protein. Kinase assays were initiated by the addition of 10 Ci of [␥-
32 P]ATP (3,000 Ci/mmol) and 20 M ATP, followed by incubation for 10 min at 37°C. 32 P-labeled myelin basic protein was absorbed onto phosphocellulose disks, and free radioactivity was removed by repeated washing with 75 mM phosphoric acid. Phosphorylation was determined by liquid scintillation.
Assay for PKC activity. PKC activity was measured in the particulate fraction as described previously (27, 31) . Muscle cells (2 ϫ 10 6 cells/ml) were incubated with ET-1 for 5 min in the presence or absence of ET A or ETB antagonist, and the reaction was terminated by rapid freezing. After homogenization, PKC activity was measured in the membrane pellet by phosphorylation of myelin basic protein, and the results are expressed as cpm per milligram of protein per minute.
Immunoblot analysis of phosphorylated MLC 20, MYPT1, and CPI-17. Phosphorylated MLC20 was determined by immunoblot using phospho-specific antibodies to MLC20 (Ser 19 ; sc-19849), MYPT1 (Thr 696 ; sc-17556), and CPI-17 (Thr 38 ; sc-17560) as described previously (31, 47). The proteins were resolved by SDS-PAGE and electrophoretically transferred on to polyvinylidene difluoride membranes. The membranes were incubated for 12 h with appropriate antibody and then for 1 h with a horseradish peroxidase-conjugated secondary antibody. The bands were identified by enhanced chemiluminescence.
Measurement of contraction in dispersed smooth muscle cells. Muscle cell contraction was measured in freshly dispersed muscle cells by scanning micrometry as described previously (27, 30, 31, 47) . A cell aliquot containing 10 4 muscle cells/ml was added to 0.1 ml of medium containing ET-1, and the reaction was terminated with 1% acrolein. Time course measurements were taken at intervals for 5 min. The mean cell length of 50 muscle cells treated with ET-1 was measured using scanning micrometry and was compared with the mean length of untreated muscle cells (mean control cell length: 128 Ϯ 5 m).
Materials. Collagenase and soybean trypsin inhibitor were obtained from Worthington Biochemical (Freehold, NJ). Western blotting and chromatography materials were obtained from Bio-Rad Laboratories (Hercules, CA). RhoA antibody was purchased from Upstate Biotechnology (Lake Placid, NY). MLC 20 phospho-antibody, CPI-17 phospho-antibody, MYPT1 phospho-antibody, Rho kinase antibody, and polyclonal antibodies to G␣ i1 G␣i2, G␣i3, G␣13, and G␣s were obtained from Santa Cruz Biotechnology (Santa Cruz, CA 
RESULTS

Expression of ET A and ET B receptors in intestinal smooth
muscle. Both ET A and ET B receptors were detected by RT-PCR on RNA extracted from cultured rabbit circular and longitudinal muscle cells in first passage using primers based on conserved sequences of human, mouse, and rat cDNAs (Fig.  1) . As shown previously (43) , the use of smooth muscle cells in first passage ensured the absence of contaminants from neural, endothelial, and interstitial cells.
Selective roles of ET A and ET B receptors in initial and sustained contraction. Exposure of muscle cells isolated separately from the circular and longitudinal muscle layers of intestine to ET-1 caused an immediate contraction that attained a peak within 30 s and was sustained for up to 10 min of observation (Fig. 2) . The initial peak contraction at 30 s was concentration dependent and was partly inhibited by selective ET A (BQ-123) and ET B (BQ-788) antagonists and abolished by a combination of the two antagonists (Figs. 2 and 3 ). The effect of each antagonist on the initial contraction was concentration dependent (Fig. 3) . In contrast, the sustained contraction determined at 5 min was abolished by the ET A antagonist but was not affected by the ET B antagonist (Fig. 3) . Studies with other agonists have shown that the initial and sustained contractions are mediated by distinct G proteins and signaling pathways (27, 31, 47) .
The involvement of both receptors in initial contraction and of ET A only in sustained contraction was corroborated by selective receptor protection using the selective antagonists (29, 30) . The technique has been validated for a variety of agonists and antagonists (29, 30) . In this study, ET A or ET B receptors were selectively protected (i.e., preserved) by treating the cells with an ET A or ET B antagonist, respectively, for ET-1 was reexamined. After selective protection of the ET A receptor, the initial contraction induced by ET-1 decreased by 46 Ϯ 4% and the residual response was abolished by the ET A antagonist but was not affected by the ET B antagonist (Fig. 4) . The converse occurred when ET B antagonist was used to protect selectively ET B receptors. In contrast, there was no decrease in sustained contraction when ET A receptors were protected, whereas no sustained contraction was observed when ET B receptors were protected. The pattern provided further support for the notion that both ET A and ET B receptors mediate initial contraction, whereas only ET A receptors mediate sustained contraction. (Fig. 5) . The results implied that ET-1 interacts with both ET A and ET B receptors: ET A receptors are coupled to activation of G␣ q and G␣ 13 , whereas ET B receptors are coupled to activation of G␣ q only.
Identification of G proteins coupled to ET
Signaling pathways mediating initial contraction and MLC 20 (21, 22, 27) . In circular muscle cells, ET-1 caused a threefold increase in PI hydrolysis within 1 min that was partly inhibited by ET A and ET B antagonists (67 Ϯ 4 and 48 Ϯ 6% inhibition, respectively) and abolished by a combination of both antagonists (94 Ϯ 6%) (Fig. 6A) . PI hydrolysis was not affected by pretreatment of the cells for 60 min with pertussis toxin (400 ng/ml), consistent with the absence of G i activation by ET-1 in these cells (Table 1 ). In permeabilized circular muscle cells, ET-1 stimulated prompt Ca 2ϩ release from sarcoplasmic stores (32 Ϯ 4% decrease in 45 Ca 2ϩ cell content within 1 min), which was completely blocked by heparin (0.1 g/ml) (3 Ϯ 6%; NS), indicating that it was mediated by activation of IP 3 receptor/ Ca 2ϩ channels (Fig. 6B ). 45 Ca 2ϩ as previously described (47) . U-73122 (1 M) and heparin (100 ng/ml) were added 10 min before addition of ET-1 (1 M). Results are expressed as the maximal decrease in steady-state 45 The initial contraction induced by ET-1 (measured at 30 s) conformed to the pattern of response in the two cell types and was blocked by inhibition of IP 3 formation with U-73122 in circular muscle cells and inhibition of arachidonic acid release with arachidonyl trifluoromethyl ketone (AACOCF 3 ) in longitudinal muscle cells (Fig. 7A) . In both cell types, the initial contraction was inhibited by the MLCK inhibitor ML-9, but it was not affected by the PKC inhibitor bisindolylmaleimide or the Rho kinase inhibitor Y-27632 (data not shown).
The changes in MLC 20 phosphorylation during the first 60 s paralleled those of initial contraction (Fig. 7C) . In both cell types, initial MLC 20 phosphorylation was abolished by ML-9 but was not affected by Y-27632 or bisindolylmaleimide. 20 phosphorylation by ET-1. We recently showed that agonist (e.g., acetylcholine, sphingosine-1-phosphate)-induced sustained contraction and MLC 20 phosphorylation are Ca 2ϩ independent and mediated cooperatively via Rho kinase phosphorylation of MYPT1 and PKC phosphorylation of CPI-17, resulting in inhibition of MLC phosphatase (31, 47) . In this study, ET-1 activated RhoA in naive circular and longitudinal muscle cells and in cells where only ET A receptors were preserved; RhoA activity was not stimulated in cells where only ET B receptors were preserved (Fig. 8) . As expected, ET-1 activated all regulatory mediators downstream of RhoA, including Rho kinase, PLD, and PKC in both circular muscle cells (Rho kinase: 465 Ϯ 53%; PLD: 281 Ϯ 36%; PKC: 382 Ϯ 47%) and longitudinal muscle cells (Rho kinase: 507 Ϯ 62%; PLD: 335 Ϯ 42%; PKC: 428 Ϯ 59%) (Fig. 9) . Dephosphorylation of phosphatidic acid, the primary product of phosphatidylcholine hydrolysis by PLD, yields diacylglycerol, which stimulates PKC activity (28) . The ET A antagonist BQ-123, but not the ET B antagonist BQ-788, inhibited all three enzymatic activities.
Signaling pathways mediating sustained contraction and MLC
Sustained contraction and MLC 20 phosphorylation induced by ET-1 (measured at 5 min) were inhibited by Y-27632 but were not affected by bisindolylmaleimide or ML-9 (Fig. 7, B  and C) . The pattern implied that PKC did not participate in inhibition of MLC phosphatase leading to phosphorylation of MLC 20 . Accordingly, ET-1 stimulated phosphorylation of MYPT1 at Thr 696 ; the phosphorylation was abolished by Freshly dispersed muscle cells were treated separately with kinase inhibitors as indicated for 10 min and then treated with ET-1 (1 M) for 30 s or 5 min. MLC20 phosphorylation was determined using phospho-specific Ser 19 antibody. Equal amounts of total protein (50 g) were loaded and confirmed by Western blotting using MLC20 antibody (data not shown). Y-27632 but was not affected by bisindolylmaleimide (Fig.  10) . Despite activation of PKC, ET-1 had no effect on CPI-17 phosphorylation at Thr 38 ( Fig. 11) . ET B -mediated activation of PP2A blocks phosphorylation of CPI-17 by PKC. We examined the possibility that the absence of CPI-17 phosphorylation by PKC could reflect dephosphorylation by an activated PP2A. In support of this notion, ET-1 induced CPI-17 phosphorylation in the presence of a low concentration of okadaic acid (1 nM), which selectively blocks PP2A. CPI-17 phosphorylation was inhibited by bisindolylmaleimide, implying that it was mediated by PKC (Fig. 11) . CPI-17 phosphorylation was also observed after blockade of ET B but not ET A receptors and in the presence of the p38 MAPK inhibitor SB-203580, implying that the upstream pathway that resulted in activation of PP2A involved stimulation of p38 MAPK via ET B receptors (Fig. 11) . response and the sustained response, which determines vascular and visceral smooth muscle tone. Wang and Bitar (44) showed partial inhibition of sustained contraction by C3 exoenzyme in dispersed colonic muscle cells and proposed a mechanism for Rho-mediated regulation of sustained contraction via cytoskeletal reorganization of heat shock protein 27. Gohla et al. (11) noted that ET-1 activated predominantly G q and G 13 and stimulated contraction and MLC 20 phosphorylation in cultured aortic smooth muscle cells. Contraction was based on photographic analysis of the changes in cell dimensions 15 min after addition of ET-1. Although the experimental design precluded identification of the receptors, G proteins, and signaling pathways mediating the initial and sustained phases of contraction, it provided evidence that contraction and MLC 20 phosphorylation in these cells involved activation of both MLCK and Rho kinase.
The present study provides a detailed analysis of the signaling pathways initiated by ET A and ET B receptors in smooth muscle. A model depicting these pathways is shown in Fig. 12. ET-1 activated G q and G 13 (21) (22) (23) 27) . Accordingly, ML-9 inhibited the initial MLC 20 phosphorylation and contraction in both cell types. As expected, contraction was inhibited selectively by U-73122 in circular muscle and by nifedipine and the cPLA 2 inhibitor AACOCF 3 in longitudinal muscle.
In contrast, the sustained phase of MLC 20 phosphorylation and contraction was mediated selectively by ET A receptors via a pathway involving sequential activation of G␣ 13 , RhoA, and Rho kinase, resulting in phosphorylation of MYPT1 and inhibition of MLC phosphatase. Although PLD and PKC, which are also downstream of RhoA (31), were activated, CPI-17 was not phosphorylated and thus did not contribute to inhibition of MLC phosphatase. In this respect, the response to ET-1 differed from the response to other G 13 /RhoA-coupled agonists, such as acetylcholine and sphingosine-1-phosphate, which cause inhibition of MLC phosphatase via phosphorylation of both MYPT1 and CPI-17 in these cells (31, 47) . The absence of CPI-17 phosphorylation by PKC reflected active dephosphorylation of CPI-17 by PP2A. PP2A was activated via a pathway involving ET B -dependent stimulation of p38 MAPK activity. The existence of this "silent" pathway, suggested by studies in other cell types linking p38 MAPK to activation of PP2A (23, 42, 45) , was confirmed by measurement of CPI-17 phosphorylation in the presence of selective kinase and phosphatase inhibitors. CPI-17 phosphorylation was unmasked in the presence of the ET B antagonist BQ-788, but not the ET A antagonist BQ-123, and in the presence of a low concentration of okadaic acid, which selectively inactivates PP2A. The resultant phosphorylation of CPI-17 was blocked by bisindolylmaleimide, providing direct confirmation that it was PKC dependent.
Our results differ from those of Niiro et al. (33) and Kitazawa et al. (19) in intact rabbit femoral artery and vas deferens muscle strips. Both groups showed that ET-1 caused phosphorylation of CPI-17 at Thr 38 . ET-1 caused phosphorylation of MYPT1 also, but only at Thr 799 , a site different from the critical phosphorylation site (Thr 696 ) responsible for inhibition of MLC phosphatase. The effects of Rho kinase and PKC inhibitors on ET-1-induced CPI-17 phosphorylation, MLC 20 phosphorylation, and muscle contraction were not examined in these studies. It is possible that the participation of MYPT1 and/or CPI-17 in inhibition of MLC phosphatase and stimulation of MLC 20 phosphorylation in response to ET-1 is tissue specific. Alternatively, ET B receptors that mediate activation of PP2A and dephosphorylation of CPI-17 may not be expressed in these tissues.
In summary, ET-1 induced an initial contraction in intestinal smooth muscle mediated additively by ET A and ET B receptors and a sustained contraction mediated exclusively by ET A receptors. The two phases of response involved distinct receptors, G proteins, and signaling pathways (Fig. 12) . The initial response reflected Ca 2ϩ -dependent activation of MLCK and phosphorylation of MLC 20 via both receptors. The sustained response reflected activation of RhoA by ET A receptors only, leading to Rho kinase-mediated phosphorylation of MYPT1, inhibition of MLC phosphatase, and phosphorylation of MLC 20 . PKC-dependent activation of the endogenous MLC phosphatase inhibitor CPI-17 was masked by an ET B -mediated 
